Poor
Mostly Unaligned
Patient Risk:
Info
Summary
Most statements are pricing/insurance/generic-competition claims with no support in the provided FDA label excerpts. A minority of medical-mechanism/indication-related statements are unsupported or partially incorrect relative to the label excerpts shown for CARDENE I.V.
Category Scores
Accurate Statements
Nicardipine hydrochloride is a calcium channel blocker.
Supported by label mechanism of action (12.1): Nicardipine inhibits transmembrane influx of calcium ions into cardiac muscle and smooth muscle.
Nicardipine hydrochloride is used to treat high blood pressure.
Supported by Indications (1.1): CARDENE I.V. indicated in adults for short-term treatment of hypertension when oral therapy is not feasible or not desirable.
Unsupported Statements
Generic versions of nicardipine hydrochloride are generally more affordable than the brand-name Cardene.
No pricing/affordability statements are present in the provided label excerpts.
A prescription for a 30-day supply of 30 mg nicardipine hydrochloride capsules might range from $20 to $50 for a generic option with insurance.
No pricing, capsule formulation, dose amount, or cost range information is present in the provided label excerpts.
Brand-name Cardene could cost more than $100-$200 without strong insurance coverage.
No pricing/insurance cost information is present in the provided label excerpts.
IV solutions or injectable forms of nicardipine hydrochloride used in hospital settings may have different pricing structures.
No pricing information by formulation or setting is present in the provided label excerpts.
Generic competition significantly drives down prices once patents expire.
No patent/market-competition/pricing-trajectory statements are present in the provided label excerpts.
Nicardipine hydrochloride is used to treat angina.
The provided label excerpts mention exacerbation of angina with oral nicardipine and induction/exacerbation of angina with CARDENE I.V. (5.1). They do not state a labeled use to treat angina.
Nicardipine hydrochloride is used to treat angina.
Not supported as an indication in the provided label excerpts; label section 1.1 lists hypertension only.
Other medications in the same class as nicardipine hydrochloride include amlodipine, nifedipine, and felodipine.
The provided label excerpts do not list class alternatives or other specific drugs.
Insurance plans vary widely in their coverage for medications like Cardene.
No insurance coverage statements are present in the provided label excerpts.
Many insurance plans will cover generic nicardipine hydrochloride, though co-pays will differ.
No insurance coverage/copay statements are present in the provided label excerpts.
Some insurance plans may require prior authorization for Cardene.
No prior authorization statements are present in the provided label excerpts.
Some insurance plans may have specific step-therapy requirements for Cardene.
No step therapy/prior authorization statements are present in the provided label excerpts.
Step-therapy requirements may require patients to try other medications first.
No step therapy statements are present in the provided label excerpts.
Contradictions
Low
AI Statement
Nicardipine hydrochloride is used to treat angina.
Label Reference
Warnings/Precautions (5.1): Increases in frequency, duration, or severity of angina have been seen in chronic therapy with oral nicardipine; induction or exacerbation of angina has been seen in less than 1% of coronary artery disease patients treated with CARDENE I.V. (mechanism not established). This frames angina as an adverse effect/exacerbation risk rather than a labeled therapeutic indication.
Important Omissions
No dosing/administration/monitoring/storage claims were made by the AI text; therefore none were assessed. If the user's intent was to evaluate dosing or administration, the provided AI statements did not address them.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
Potential risk is mainly from unsupported/incorrect therapeutic framing (angina treatment) and from misinformation about cost/insurance. The provided label excerpts do not support using CARDENE I.V. to treat angina; section 5.1 describes angina exacerbation/induction.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Low |
Recommendation
Mostly Unaligned
Primary Issue
Multiple non-label-supported claims (pricing/insurance/patent-market effects) and an on-label mismatch implying angina treatment use.
Suggested Improvement
Limit statements to label-supported content for CARDENE I.V. In particular, do not claim angina treatment as an indication; if mentioning angina, align with label language describing possible angina exacerbation.